- Home
- RPRX
RPRX
Royalty Pharma plc
as 04-25-2025 4:00pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 14.2B | IPO Year: | 2020 |
| Target Price: | $42.50 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.91 | EPS Growth: | -24.54 |
| 52 Week Low/High: | $24.05 - $34.20 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,263,576,000 | Revenue Growth: | -3.86% |
| Revenue Growth (this year): | 31.56% | Revenue Growth (next year): | 5.94% |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Royalty Pharma (NasdaqGS:RPRX) Declares US$0.22 Dividend for Q2 2025
GlobeNewswire
5 days ago
Royalty Pharma Declares Second Quarter 2025 Dividend
GlobeNewswire
9 days ago
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
18 days ago
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
GlobeNewswire
a month ago
Royalty Pharma Announces Upcoming Investor Day
Insider Monkey
a month ago
Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility?
GlobeNewswire
2 months ago
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
Insider Monkey
2 months ago
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.